Redirecting effector T cells through their IL-2 receptors

Journal of Immunology

Volumn 162, Issue 1, 1999, Pages 359-365

  Lustgarten, Joseph ^a   Marks, James ^b   Sherman, Linda A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND; HLA A ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GROWTH INHIBITORS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032931836     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kappler, J. W., N. Roehm, and P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273.
2. - thymocytes. Nature 333:742.
3. Cabaniols, J. P., R. Cibotti, P. Kourilsky, K. Kosmatopoulos, and J. M. Kanellopoulos. 1994. Dose-dependent T cell tolerance to an immunodominant self peptide. Eur. J. Immunol. 24:1743.
4. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185:883.
5. Morgan, D. J., H. T. C. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643.
6. Janeway C. A., and K. Bottomly. 1994. Signal and signs for lymphocytes responses. Cell 76:275.
7. Sotomayor, E. M., I. Borrello, and H. I. Levitsky. 1996. Tolerance and cancer: a critical issue in tumor immunology. Crit. Rev. Oncog. 7:443.
8. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992 Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1039.
9. Townsend, S. E., and J. P. Allison. 1993. Tumor rejection after direct costimulation of CD8. T cells by B7-transfected melanoma cells. Science 259:368.
10. Greenberg, P. D. 1991. T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281.
11. Vella, A. T., S. Dow, T. A. Potter, J. Kappler, and P. Marrack. 1998. Cytokine-induced survival of activated T cell in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95:3810.
12. Grimm, E. A., A. Maxumder, H. Z. Zhang, and S. A. Rosenberg. 1982. Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1823.
13. Hayakama, K., M. A. Salmeron, D. R. Parkinson, A. B. Markowitz, E. C. von Eschenbach, S. S. Legha, C. M. Balch, M. I. Ross, L. B. Augustus, and K. Itoh. 1991. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal-cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J. Immunother. 10:313.
14. Reisfeld, R. A., and S. D. Gillies. 1996. Antibody-interleukin 2 fusion protein: a new approach to cancer therapy. J. Clin. Lab. Anal. 10:160.
15. Becker, J. C., N. Varki, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. An antibody-interleukin-2 fusion protein overcomes tumor heterogenicity by induction of a cellular response. Proc. Natl. Acad. Sci. USA 93:7826.
16. Xiang, R., H. N. Lode, C. S. Dolman, T. Dreier, N. Varki, X. Qian, K-M. Lo, Y. Lan, M. Super, S. D. Gillies, and R. A. Reisfeld. 1997. Elimination of establish murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57:4948.
17. Becker, J. C., J. D. Pancook, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183:2361.
18. Becker, J. C., N. Varki, S. D. Gillies, K. Furukawa, and R. A. Reisfeld. 1996. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest. 98:2801.
19. Lustgarten, J., M. Theobald, C. Labadie, D. LaFace, P. Peterson, M. L. Disis, M. A. Cheever, and L. A. Sherman. 1997. Identification of Her-2/ncu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum. Immunol. 52:109.
20. Melief, C. J. M., and W. M. Kast. 1995. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145:167.
21. + T cells. Eur. J. Immunol. 22:1013.
22. + T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157:978.
23. Schier, R., A. McCall, G. P. Adams, K. W. Marshall, H. Merritt, M. Yim, R. S. Crawford, L. M. Weiner, C. Marks, and J. D. Marks. 1996. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263:551.
24. Clarke, S.H., K. Huppi, D. Ruezinsky, L. Staudt, W. Gerhard, and M. Weigert. 1985. Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J. Exp. Med. 161:687.
25. Mosman, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55.
26. Sabzevari, H., S. D. Gillies, B. M. Mueller, J. D. Pancook, and R. A. Reisfeld. 1994. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad. Sci. USA 91:9626.
27. Berke, G. 1995. The CTL's kiss of death. Cell 81:9.
28. Liu, C.C., P. M. Persechini, and J. D. Young. 1995. Perforin and lymphocyte-mediated cytolysis. Immunol. Rev. 146:145.
29. Dillman, R. O. 1994. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother. 9:183.
30. Naramura, M., S. D. Gillies, J. Mendelsohn, R. A. Reisfeld, and B. M. Mueller. 1994. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL-2 fusion protein against melanoma cells. Immunol. Lett. 39:91.
31. + T lymphocyte clones. J. Immunol. 158:561.
32. de Gast, G. C., J.G. van de Winkel, and B.E. Bast. 1997. Clinical perspectives of bispecific antibodies in cancer. Cancer Immunol. Immunother. 45:121.